Get the Stockscreener App
143.24
4.16%
5.6966
Krystal Biotech Inc stock is traded at $143.24, with a volume of 99,458.
It is up +4.16% in the last 24 hours and down -3.31% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$137.54
Open:
$137.93
24h Volume:
99,458
Relative Volume:
0.26
Market Cap:
$4.14B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
47.91
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+4.30%
1M Performance:
-3.31%
6M Performance:
-5.33%
1Y Performance:
-22.31%
1-Day Range:
$137.93
$143.54
1-Week Range:
$132.31
$143.54
52-Week Range:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
143.18 | 4.01B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.51 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.21 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.89 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
642.57 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.94 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Astrana Health And 2 Insider Favorites For High Growth - simplywall.st
Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2025 Earnings Call Transcript - MSN
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN
Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com
Local biotech co-founder named to Forbes 50 Over 50 - MSN
Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest
Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest
Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN
Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest
Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest
Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q2 2025 Results - TipRanks
Krystal Biotech price target lowered to $166 from $176 at Citi - TipRanks
Krystal Biotech stock price target lowered to $182 at BofA on growth concerns - Investing.com Nigeria
Krystal Biotech Exceeds Q2 2025 Earnings Estimates with $96 Million Revenue, $1.33 EPS - AInvest
Krystal Biotech sees revenue growth but anticipates dip due to summer vacations - The Business Journals
Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy - AInvest
Krystal Biotech, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating - TipRanks
Krystal Biotech shares fall 12.71% intraday after missing Q2 earnings estimates. - AInvest
Krystal Biotech Q2 2025 slides: VYJUVEK drives growth amid global expansion - Investing.com Canada
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips - Investing.com Canada
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Transcript : Krystal Biotech, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Krystal Biotech shares jump as Q2 results exceed expectations By Investing.com - Investing.com India
Krystal Biotech shares jump as Q2 results exceed expectations - Investing.com
Krystal Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Krystal Biotech Grows Revenue On VYJUVEK’s Expanding Global Reach - Finimize
Krystal Biotech Q2 Earnings, Revenue Rise - MarketScreener
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $96.0M, vs. FactSet Est of $92.0M - MarketScreener
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - TradingView
Krystal Biotech earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech's Q2 revenue rises 37% to $96 mln - MarketScreener
Krystal Biotech, Inc. Q2 Profit Advances, But Misses Estimates - Nasdaq
Krystal Biotech Earnings: $96M Revenue Quarter, Japan Expansion, and Pipeline Breakthroughs Revealed - Stock Titan
What drives Krystal Biotech Inc. stock priceGrow your portfolio with growth-oriented stocks - Jammu Links News
Is Krystal Biotech Inc. a good long term investmentUnlock real-time stock alerts for quick profits - Jammu Links News
How volatile is Krystal Biotech Inc. stock compared to the marketTrack emerging stocks with high growth potential - Jammu Links News
What are analysts’ price targets for Krystal Biotech Inc. in the next 12 monthsInvest smarter with expert stock recommendations - Jammu Links News
Is it the right time to buy Krystal Biotech Inc. stockExplosive capital gains - Jammu Links News
What is the dividend policy of Krystal Biotech Inc. stockDiscover dynamic stocks ready to soar - Jammu Links News
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Krystal Biotech Inc Stock (KRYS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krishnan Suma | President, R&D |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,389 |
208,350 |
1,508,056 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,435 |
2,019,225 |
1,443,276 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Krish S | President and CEO |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
0.37%
2.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):